https://www.live-feeds.com/feed/xenon-pauses-phase-3-depression-trials-after-psychosis-eventsContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/xenon-pauses-phase-3-depression-trials-after-psychosis-eventshttps://www.live-feeds.com/feed/xenon-pauses-phase-3-depression-trials-after-psychosis-events#u77534Sun, 20 Sep 2026 14:50:16 +0000Xenon Pharmaceuticals has voluntarily paused new enrollment in its Phase 3 clinical trials for bipolar depression and major depressive disorder. The company halted the studies following neuropsychiatric side effects, specifically psychosis events. This setback occurred the same day Xenon submitted a New Drug Application to the FDA for azetukalner, a drug intended to treat focal seizures. Despite the regulatory filing for its epilepsy treatment, Xenon shares fell between 30% and 32.2% as investors reacted to the psychiatry program's instability.Why it mattersPhase 3 trials are the final st